These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 32207294)

  • 1. Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules.
    Babu T; Sarkar A; Karmakar S; Schmidt C; Gibson D
    Inorg Chem; 2020 Apr; 59(7):5182-5193. PubMed ID: 32207294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability, Reduction, and Cytotoxicity of Platinum(IV) Anticancer Prodrugs Bearing Carbamate Axial Ligands: Comparison with Their Carboxylate Analogues.
    Chen S; Yao H; Zhou Q; Tse MK; Gunawan YF; Zhu G
    Inorg Chem; 2020 Aug; 59(16):11676-11687. PubMed ID: 32799457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum(IV)-Estramustine Multiaction Prodrugs Are Effective Antiproliferative Agents against Prostate Cancer Cells.
    Karmakar S; Kostrhunova H; Ctvrtlikova T; Novohradsky V; Gibson D; Brabec V
    J Med Chem; 2020 Nov; 63(22):13861-13877. PubMed ID: 33175515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pt(IV) pro-drugs with an axial HDAC inhibitor demonstrate multimodal mechanisms involving DNA damage and apoptosis independent of cisplatin resistance in A2780/A2780cis cells.
    Almotairy ARZ; Montagner D; Morrison L; Devereux M; Howe O; Erxleben A
    J Inorg Biochem; 2020 Sep; 210():111125. PubMed ID: 32521289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiaction Pt(IV) Prodrugs Releasing Cisplatin and Dasatinib Are Potent Anticancer and Anti-Invasive Agents Displaying Synergism between the Two Drugs.
    Markova L; Maji M; Kostrhunova H; Novohradsky V; Kasparkova J; Gibson D; Brabec V
    J Med Chem; 2024 Jun; 67(11):9745-9758. PubMed ID: 38819023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate.
    Qiao X; Gao YY; Zheng LX; Ding XJ; Xu LW; Hu JJ; Gao WZ; Xu JY
    Eur J Med Chem; 2021 Nov; 223():113730. PubMed ID: 34388483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of axial ligands to promote the photoactivation of BODIPY-conjugated platinum(IV) anticancer prodrugs.
    Yao H; Gunawan YF; Liu G; Tse MK; Zhu G
    Dalton Trans; 2021 Oct; 50(39):13737-13747. PubMed ID: 34519297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanding the Arsenal of Pt
    Yempala T; Babu T; Karmakar S; Nemirovski A; Ishan M; Gandin V; Gibson D
    Angew Chem Int Ed Engl; 2019 Dec; 58(50):18218-18223. PubMed ID: 31599054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multitargeted Platinum(IV) Anticancer Complexes Bearing Pyridinyl Ligands as Axial Leaving Groups.
    Zhou Q; Chen S; Xu Z; Liu G; Zhang S; Wang Z; Tse MK; Yiu SM; Zhu G
    Angew Chem Int Ed Engl; 2023 Apr; 62(18):e202302156. PubMed ID: 36878864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
    Gibson D
    J Inorg Biochem; 2021 Apr; 217():111353. PubMed ID: 33477089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and investigation of photoactivatable platinum(iv) prodrug complexes of cisplatin.
    Lee VEY; Chin CF; Ang WH
    Dalton Trans; 2019 Jun; 48(21):7388-7393. PubMed ID: 30957798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
    Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
    Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs?
    Schmidt C; Babu T; Kostrhunova H; Timm A; Basu U; Ott I; Gandin V; Brabec V; Gibson D
    J Med Chem; 2021 Aug; 64(15):11364-11378. PubMed ID: 34342437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
    Wang Z; Deng Z; Zhu G
    Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What do we know about the reduction of Pt(IV) pro-drugs?
    Wexselblatt E; Gibson D
    J Inorg Biochem; 2012 Dec; 117():220-9. PubMed ID: 22877926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pt(IV) Complexes in the Search for Novel Platinum Prodrugs with Promising Activity.
    Aher S; Zhu J; Bhagat P; Borse L; Liu X
    Top Curr Chem (Cham); 2024 Feb; 382(1):6. PubMed ID: 38400859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorogenic platinum(IV) complexes as potential predictors for the design of hypoxia-activated platinum(IV) prodrugs.
    Marsh JW; Hacker L; Huang S; Boulet MHC; White JRG; Martin LAW; Yeomans MA; Han HH; Diez-Perez I; Musgrave RA; Hammond EM; Sedgwick AC
    Dalton Trans; 2024 Sep; 53(35):14811-14816. PubMed ID: 39169877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, Spectroscopic Properties, Crystal Structure And Biological Evaluation of New Platinum Complexes with 5-methyl-5-(2-thiomethyl)ethyl Hydantoin.
    Bakalova AG; Buyukliev RT; Nikolova RP; Shivachev BL; Mihaylova RA; Konstantinov SM
    Anticancer Agents Med Chem; 2019; 19(10):1243-1252. PubMed ID: 30767754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiproliferative activity of a series of cisplatin-based Pt(IV)-acetylamido/carboxylato prodrugs.
    Ravera M; Gabano E; Zanellato I; Fregonese F; Pelosi G; Platts JA; Osella D
    Dalton Trans; 2016 Mar; 45(12):5300-9. PubMed ID: 26903367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.
    Gabano E; Ravera M; Zanellato I; Tinello S; Gallina A; Rangone B; Gandin V; Marzano C; Bottone MG; Osella D
    Dalton Trans; 2017 Oct; 46(41):14174-14185. PubMed ID: 28984330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.